patients scheduled for knee arthroplasty
Conditions
Interventions
Rocuronium bromide (0.9 mg/kg) will be administered before ischemia.
Placebo (same volume of saline) will be administered before ischemia.
Sponsors
Kobe university
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1)Patients scheduled for knee arthroplasty. 2)Female patients aged 50-79 years old. 3)Patients who agreed to a written informed consent.
Exclusion criteria
Exclusion criteria: 1)Patients with preoperative ALT > 100 U/L. 2)Patients with preoperative Cr > 1.5 mg/dL. 3)Patients with a history of neuromuscular disease. 4)Patients with drug sensitivity and allergy. 5)Pregnant women and patients who may be pregnant or breast-feeding patients. 6)Patients receiving medications known to interact with muscle relaxants. 7)Patients who are judged to be inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Amount of change in plasma malondialdehyde concentration before and after ischemia. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Changes in myoglobin, CK, AST, LDH, potassium, lactic acid, uric acid and hypoxanthine concentrations before and after ischemia. 2)Amount of change in quadriceps muscle strength before and after surgery. | — |
Countries
Japan
Contacts
Public ContactShinya Taguchi
Kobe university graduate school of medicine Division of anesthesiology, Department of surgery related
Outcome results
None listed